Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CISPD-1
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
- NCT03750669 ↗
- Completed
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Focused
We haven't built an HCP commentary report on CISPD-1 (AG regimen and mFolfirinox in Pancreatic Adenocarcinoma Resectable) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CISPD-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Sequential Use of Nab-paclitaxel Plus Gemcitabine and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer: A Randomized Control Study
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Pancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy
- Interventions
- AG regimen; mFolfirinox
- Arms
- Neoadjuvant Chemotherapy · Experimental
- control · No intervention
- Enrollment
- 324
- Primary outcomes
- event-free survival (EFS)
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Start
- Oct 20, 2018
- Primary completion
- Nov 1, 2024
- Results posted
- No
- Registry record
- NCT03750669 · updated May 13, 2025